Compare SSRM & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSRM | ORKA |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.1B |
| IPO Year | 1997 | 1997 |
| Metric | SSRM | ORKA |
|---|---|---|
| Price | $35.34 | $93.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $32.74 | ★ $92.50 |
| AVG Volume (30 Days) | ★ 2.3M | 728.6K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 243.41 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,629,637,000.00 | N/A |
| Revenue This Year | $56.48 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 63.68 | N/A |
| 52 Week Low | $18.19 | $14.67 |
| 52 Week High | $39.44 | $115.52 |
| Indicator | SSRM | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 43.97 |
| Support Level | $28.41 | $83.25 |
| Resistance Level | $36.40 | $97.02 |
| Average True Range (ATR) | 1.27 | 4.87 |
| MACD | -0.60 | -0.63 |
| Stochastic Oscillator | 20.60 | 37.62 |
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.